Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Smartinhaler

- PMLiVE

NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia

The recommendation makes Scemblix the first treatment in its class to be authorised in Britain

- PMLiVE

Alzheimer’s Research UK supports government plans for clinical research

The charity has suggested creating a Dementia Medicines Taskforce in order to address diseases like Alzheimer's

Scanning for Health Indicators and Risks Through Your Smartphone

Vlado Bosanac, Co-Founder & Head of Strategy and Revenue Growth at Advanced Human Imaging, dives into the implications of increased integration of tech and data into daily life for the...

Impetus Digital

- PMLiVE

NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis

The recommendation will give those living with the condition in England and Wales access to a new treatment option

- PMLiVE

The digital-first launch: the key to connected stakeholder experiences?

During the COVID-19 pandemic, a new digital-first launch model emerged as a gamechanger for driving better customer experiences. Here, Senior Consultant Srividya Sekar; Senior Associate Consultant, Erin Johnstone; and Associate...

Avalere Health

- PMLiVE

ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE

With the Health and Care Act safely passed, Oli Hudson introduces six key stakeholders that will loom large in the new landscape.

Wilmington Healthcare

- PMLiVE

Eli Lilly’s Verzenios recommended by NICE as combination therapy for early-stage breast cancer

The trial results showed a drop of 32% in cancer recurrence when using Verzenios in combination with endocrine therapy

- PMLiVE

Shionogi Europe and NHS England agree on antibiotic subscription model

The antibiotic Fetcroja, along with Zavicefta, will be made available as an option to help address antimicrobial resistance

- PMLiVE

Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed

Wilmington Healthcare’s State of the Nation prescribing report shows that spending on sertraline, commonly used to treat depression and anxiety, increased by 305.5% between 2019/20 and 2020/21 while overall spend...

Wilmington Healthcare

- PMLiVE

NICE recommends Vazkepa for patients at risk of stroke and heart attacks in England and Wales

In England, more than six million people live with cardiovascular disease, costing the NHS around £7.4bn per year

Engaging Patients “Just-In-Time” with Machine Learning

Omri Shor, Co-founder & CEO of Medisafe, explores how Pharma companies can use digital therapeutics for advancing and supporting the patient journey, how new digital health tools are driving deeper...

Impetus Digital

- PMLiVE

NICE recommends Sanofi and Regeneron’s Libtayo for advanced CSCC

Eligible patients will now be able to access the treatment through the NHS in England

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links